on TME PHARMA N.V. (isin : NL0015000YE1)
TME Pharma's Semi-Annual Report and Financial Restructuring
TME Pharma N.V., a biotechnology firm based in Berlin, has released its semi-annual results. The company underwent a significant reorganization, transitioning to a leaner staffing model, which reduced costs substantially. This change coincided with the appointment of a new CEO, Diede van den Ouden, in June 2025.
The company raised €1.7 million through bond issuance in May 2025, followed by an additional €500,000 in August, highlighting investor confidence. Despite a reduction in workforce, TME Pharma continues to focus on its NOX A12 and NOX E36 assets, seeking partnerships and profitable ventures.
Financially, TME Pharma recorded a net loss of €2.1 million for H1 2025 but reduced losses compared to €3.2 million in H1 2024. Turnover reached €27k, up from zero the previous year. The cash position stands at €2.06 million, with financial visibility until May 2026.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TME PHARMA N.V. news